Wnt signaling in regeneration
A developmental pathway reused in adult repair — and a validated drug target in bone.
Wnt signalling patterns tissue during embryonic development and is reactivated in adult repair. In the canonical pathway, Wnt ligands stabilise β-catenin, which enters the nucleus and activates target genes. In bone, this pathway promotes osteoblast differentiation and survival, making it a central regulator of bone mass.
Its clinical validation came from human genetics. Mutations in the Wnt inhibitor sclerostin cause conditions of extremely high bone mass — a natural experiment showing that removing the brake builds bone. Antibodies against sclerostin were developed on exactly that reasoning and are now used in Osteoporosis and bone density, one of the clearer paths from pathway biology to therapy.
Wnt also mediates mechanical signalling: osteocytes reduce sclerostin production under load, which is part of how the skeleton adapts to use — relevant to Distraction osteogenesis. It interacts with TGF-β and BMP signalling throughout, and drives Stem cell differentiation toward bone lineages.
Related articles
- BoneOsteoporosis and bone densityWhat happens when the remodeling cycle tips toward resorption, and why density is only part of the story.
- CellsStem cell differentiationHow an uncommitted cell chooses a fate — under chemical, mechanical, and spatial instruction.
- SignalingTGF-β signalingThe superfamily containing the BMPs — and a signal whose effect depends entirely on context.
- BoneOsteoblasts and osteoclastsThe two opposing cell types whose balance determines whether bone is built or lost.
- BoneDistraction osteogenesisGrowing new bone by pulling it apart slowly — a reminder that mechanical force is itself a biological signal.
- SignalingGrowth factor deliveryPotent, unstable, and short-lived — why delivering growth factors is harder than choosing them.